Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Investing Profile

Mark Chin

InvestorVC
Managing Director at Arix Bioscience
Arix Bioscience Managing Director
$100K - $5.0M
$1.5M
13
CompanyStageDateRound SizeTotal Raised
Ottimo Pharma
Series ADec 2024$140M
$140M
Co-investors: Peter Thompson (OrbiMed)
Vicebio
Series BSep 2024$100M
$100M
Evommune
Series BApr 2023$50M
$260M
Co-investors: Rob Hopfner (Pivotal bioVenture Partners), Ash Khanna (Pivotal bioVenture Partners), Derek DiRocco (RA Capital)
Ensoma
Series BJan 2023$85M
$210M
Co-investors: Kush Parmar (5am Ventures), Stephen Knight (F-Prime Capital Partners), Kouki Harasaki (Bioluminescence Ventures)
Disc Medicine
Post Ipo EquityDec 2022$54M
Post Ipo EquitySep 2021$90M
$440M
Co-investors: Mona Ashiya (OrbiMed), Kevin Bitterman (Atlas Venture)
VelosBio
Series BJul 2020$140M
Series AOct 2018$58M
$200M
Co-investors: Joseph Anderson (Soffinova Partners)
Imara
Series BMar 2019$63M
$63M
Co-investors: David Bonita (OrbiMed), Joseph Anderson (Soffinova Partners)
Harpoon Therapeutics
Series CNov 2018$70M
Series BMay 2017$45M
$120M
Co-investors: Luke Evnin (MPM Capital)